Table 1

EF5 binding in intraperitoneal malignancies

Patient no.HistologyCohortSpecimenSectioning levels% of reference binding at each levelaIntraspecimen median (range)bInterspecimen median (range)cInterspecimen mean (SE)d
1GISTeSarcomaA1, 2, 3, and 40.3, 0.1, 0.2, and 0.60.3 (0.5)0.2 (0.3)0.4 (0.5)
B1, 2, and 30, 0, and 0.70.0 (0.7)
2GISTSarcomaA1, 2, and 31.4, 1.4, and 1.11.4 (0.3)1.41.4 (1.7)
3Ovarian CAOvarianA1 and 26.3 and 4.75.5 (1.6)5.5 (6.2)5.1 (2.8)
B18.38.3
C1 and 21.8 and 2.32.1 (0.5)
4Ovarian CAOvarianA13.23.23.2 (67.5)26.2 (11.0)
B1 and 295.3 and 44.169.7 (51.2)
C1 and 22.8 and 1.62.2 (1.2)
5Colon CAGIA16.06.06.2 (32.8)15.0 (7.5)
B1 and 222.4 and 54.938.7 (32.5)
C16.46.4
D15.95.9
6Colon CAGIA150.050.029.7 (35.9)29.2 (10.1)
B118.418.4
C1 and 28.5 and 19.714.1 (11.2)
D140.940.9
7Colon CAGIA1 and 22.3 and 1.62.0 (0.7)8.6 (15.4)8.3 (3.2)
B1 and 218.7 and 16.017.4 (2.7)
C1 and 213.3 and 4.79.0 (8.6)
D1 and 22.5 and 14.68.6 (12.1)
E1 and 25.1 and 4.54.8 (0.6)
8Small bowel CAGIAf1, 2, and 32.3, 0.2, and 1.31.3 (2.1)1.31.4 (1.7)
9Appendiceal CAGIA10.30.30.3 (1.5)1.0 (1.3)
B10.20.2
C1 and 21.6 and 1.71.7 (0.1)
  • a EF5 binding is expressed as a percentage of maximum hypoxia marker binding in tissue from the same patient. Reference binding values were not available for patients 4, 7, and 9. For these patients, the percentage of reference binding was calculated based on the average reference binding level in other patients of the same disease cohort.

  • b Median and range (largest-smallest) of values for each specimen.

  • c Median and range (largest-smallest) of median values of specimens for each patient.

  • d The model-based mean and SE of specimens for each patient.

  • e GIST, gastrointestinal stromal tumor; CA, carcinoma.

  • f An additional three specimens from patient 8 were found by histological analysis to contain no tumor and are thus not included in these data.